Diagnostic pathways and delay among tuberculosis patients in Stockholm, Sweden: a retrospective observational study.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
04 Feb 2019
Historique:
received: 30 05 2018
accepted: 21 01 2019
entrez: 6 2 2019
pubmed: 6 2 2019
medline: 1 5 2019
Statut: epublish

Résumé

Asylum seekers in Sweden are offered tuberculosis (TB) screening at a voluntary post-arrival health examination. The role of this screening in improving the TB diagnostic pathway has not been previously evaluated. The aim of this study was to determine diagnostic pathways for active TB cases and compare diagnostic delays between different pathways. Retrospective review of medical records of patients reported with active TB in Stockholm in 2015, using a structured and pre-coded form. Seventy-one percent of patients actively sought health care due to symptoms. As for source of referral to TB specialist clinic, 15% came from screening of eligible migrants, of whom the majority were asymptomatic. Among asylum seekers, 69% were identified through screening at a health examination (HE). The main sources of referral to TB clinics were emergency departments (27%) and primary health care centers (20%). Median health care provider delay was significantly longer in patients identified through migrant screening in health examination. Screening at a health examination was the main pathway of active TB detection among mainly asymptomatic and non-contagious asylum seekers but contributed modestly to total overall TB case detection. In these patients TB was diagnosed early in a non-contagious phase of the disease. Further research is required to assess the effectiveness and cost-effectiveness of HE TB screening as well as inclusion of other groups of migrants from high incidence countries in the screening program in terms of impact on delay, transmission and treatment outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Asylum seekers in Sweden are offered tuberculosis (TB) screening at a voluntary post-arrival health examination. The role of this screening in improving the TB diagnostic pathway has not been previously evaluated. The aim of this study was to determine diagnostic pathways for active TB cases and compare diagnostic delays between different pathways.
METHODS METHODS
Retrospective review of medical records of patients reported with active TB in Stockholm in 2015, using a structured and pre-coded form.
RESULTS RESULTS
Seventy-one percent of patients actively sought health care due to symptoms. As for source of referral to TB specialist clinic, 15% came from screening of eligible migrants, of whom the majority were asymptomatic. Among asylum seekers, 69% were identified through screening at a health examination (HE). The main sources of referral to TB clinics were emergency departments (27%) and primary health care centers (20%). Median health care provider delay was significantly longer in patients identified through migrant screening in health examination.
CONCLUSIONS CONCLUSIONS
Screening at a health examination was the main pathway of active TB detection among mainly asymptomatic and non-contagious asylum seekers but contributed modestly to total overall TB case detection. In these patients TB was diagnosed early in a non-contagious phase of the disease. Further research is required to assess the effectiveness and cost-effectiveness of HE TB screening as well as inclusion of other groups of migrants from high incidence countries in the screening program in terms of impact on delay, transmission and treatment outcomes.

Identifiants

pubmed: 30717738
doi: 10.1186/s12889-019-6462-5
pii: 10.1186/s12889-019-6462-5
pmc: PMC6360687
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

151

Subventions

Organisme : Forskningsrådet om Hälsa, Arbetsliv och Välfärd
ID : 2015-00304
Organisme : Hjärt-Lungfonden
ID : 20160508

Références

Int J Tuberc Lung Dis. 2013 Mar;17(3):289-98
pubmed: 23407219
Int J Tuberc Lung Dis. 2013 Apr;17(4):432-46
pubmed: 23485377
Eur Respir J. 2014 Apr;43(4):1159-71
pubmed: 24114966
Eur Respir J. 2015 Apr;45(4):928-52
pubmed: 25792630
Lancet. 2015 May 2;385(9979):1799-1801
pubmed: 25814376
Eur Respir J. 2015 Dec;46(6):1563-76
pubmed: 26405286
Int J Tuberc Lung Dis. 2017 Jun 1;21(6):624-637
pubmed: 28482956
Int J Tuberc Lung Dis. 2017 Aug 1;21(8):840-851
pubmed: 28786791
Int J Tuberc Lung Dis. 2017 Sep 1;21(9):965-976
pubmed: 28826445
Int J Tuberc Lung Dis. 2017 Sep 1;21(9):977-989
pubmed: 28826446
JAMA. 1997 Jul 23-30;278(4):304-7
pubmed: 9228436

Auteurs

Anna Wikell (A)

Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden. annamwikell@gmail.com.

Helena Åberg (H)

Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden.

Jad Shedrawy (J)

Department of Public Health Sciences, Karolinska Institutet, 171 77, Stockholm, Sweden.

Isac Röhl (I)

Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden.

Jerker Jonsson (J)

Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden.
The Public Health Agency of Sweden, 171 65, Solna, Sweden.

Ingela Berggren (I)

Department of Communicable Disease Control & Prevention, Stockholm County Council, 118 91, Stockholm, Sweden.

Charlotte Buxbaum (C)

Department of Pediatrics, Karolinska University Hospital Huddinge, 141 86, Stockholm, Sweden.

Knut Lönnroth (K)

Department of Public Health Sciences, Karolinska Institutet, 171 77, Stockholm, Sweden.
Centre for Epidemiology and Community Medicine, Stockholm County, 104 31, Stockholm, Sweden.

Judith Bruchfeld (J)

Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden.
Department of Infectious Diseases, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH